An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease

Trial Profile

An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Ursodeoxycholic acid (Primary)
  • Indications Polycystic liver disease
  • Focus Therapeutic Use
  • Acronyms CURSOR
  • Most Recent Events

    • 17 Apr 2016 Primary endpoint has not been met (Effect of UDCA on total liver volume) according to results presented at The International Liver Congress™ 2016.
    • 17 Apr 2016 Results presented at The International Liver Congress™ 2016.
    • 06 Apr 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top